| Hit and lead criteria in drug discovery for infectious diseases of the developing world K Katsuno, JN Burrows, K Duncan, RH Van Huijsduijnen, T Kaneko, ... Nature Reviews drug discovery 14 (11), 751-758, 2015 | 571 | 2015 |
| Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives F Alves, G Bilbe, S Blesson, V Goyal, S Monnerat, C Mowbray, ... Clinical microbiology reviews 31 (4), 10.1128/cmr. 00048-18, 2018 | 192 | 2018 |
| Concise synthesis of enantiomerically pure phenylalanine, homophenylalanine, and bishomophenylalanine derivatives using organozinc chemistry: NMR studies of amino acid-derived … RFW Jackson, RJ Moore, CS Dexter, J Elliott, CE Mowbray The Journal of Organic Chemistry 63 (22), 7875-7884, 1998 | 143 | 1998 |
| Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate CE Mowbray, C Burt, R Corbau, S Gayton, M Hawes, M Perros, I Tran, ... Bioorganic & medicinal chemistry letters 19 (20), 5857-5860, 2009 | 120 | 2009 |
| Treatment options for second-stage gambiense human African trypanosomiasis G Eperon, M Balasegaram, J Potet, C Mowbray, O Valverde, F Chappuis Expert review of anti-infective therapy 12 (11), 1407-1417, 2014 | 114 | 2014 |
| The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern R Abdelnabi, CS Foo, D Jochmans, L Vangeel, S De Jonghe, ... Nature Communications 13 (1), 719, 2022 | 112 | 2022 |
| Structure−Activity Relationships of 1,4-Dihydro-(1H,4H)-quinoxaline-2,3-diones as N-Methyl-d-aspartate (Glycine Site) Receptor Antagonists. 1. Heterocyclic … MJ Fray, DJ Bull, CL Carr, ECL Gautier, CE Mowbray, A Stobie Journal of medicinal chemistry 44 (12), 1951-1962, 2001 | 100 | 2001 |
| Drug discovery for kinetoplastid diseases: future directions SPS Rao, MP Barrett, G Dranoff, CJ Faraday, CR Gimpelewicz, A Hailu, ... ACS infectious diseases 5 (2), 152-157, 2018 | 89 | 2018 |
| Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1 R Corbau, J Mori, C Phillips, L Fishburn, A Martin, C Mowbray, W Panton, ... Antimicrobial agents and chemotherapy 54 (10), 4451-4463, 2010 | 77 | 2010 |
| Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis D Caridha, B Vesely, K van Bocxlaer, B Arana, CE Mowbray, S Rafati, ... International Journal for Parasitology: Drugs and Drug Resistance 11, 106-117, 2019 | 73 | 2019 |
| Novel amino-pyrazole ureas with potent in vitro and in vivo antileishmanial activity CE Mowbray, S Braillard, W Speed, PA Glossop, GA Whitlock, KR Gibson, ... Journal of medicinal chemistry 58 (24), 9615-9624, 2015 | 71 | 2015 |
| Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis K Van Bocxlaer, D Caridha, C Black, B Vesely, S Leed, RJ Sciotti, ... International Journal for Parasitology: Drugs and Drug Resistance 11, 129-138, 2019 | 68 | 2019 |
| Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays LH Jones, G Allan, O Barba, C Burt, R Corbau, T Dupont, T Knöchel, ... Journal of medicinal chemistry 52 (4), 1219-1223, 2009 | 62 | 2009 |
| Polycycle construction via cascade radical fragmentation transannulation-cyclisation processes CE Mowbray, G Pattenden Tetrahedron letters 34 (1), 127-130, 1993 | 60 | 1993 |
| The role of modern drug discovery in the fight against neglected and tropical diseases JN Burrows, RL Elliott, T Kaneko, CE Mowbray, D Waterson MedChemComm 5 (6), 688-700, 2014 | 54 | 2014 |
| In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series M Van den Kerkhof, D Mabille, E Chatelain, CE Mowbray, S Braillard, ... International Journal for Parasitology: Drugs and Drug Resistance 8 (1), 81-86, 2018 | 52 | 2018 |
| Piperazine derivatives D Middleton, C Mowbray, P Stephenson, D Williams US Patent App. 10/910,984, 2005 | 40 | 2005 |
| DNDI-6148: a novel benzoxaborole preclinical candidate for the treatment of visceral leishmaniasis CE Mowbray, S Braillard, PA Glossop, GA Whitlock, RT Jacobs, J Speake, ... Journal of medicinal chemistry 64 (21), 16159-16176, 2021 | 38 | 2021 |
| Open Science Discovery of Potent Non-Covalent SARS-CoV-2 Main Protease Inhibitors COVID Moonshot Consortium, H Achdout, A Aimon, DS Alonzi, R Arbon, ... BioRxiv, 2020.10. 29.339317, 2020 | 36 | 2020 |
| Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist CE Mowbray, AS Bell, NP Clarke, M Collins, RM Jones, CAL Lane, ... Bioorganic & medicinal chemistry letters 21 (21), 6596-6602, 2011 | 36 | 2011 |
